Covid-19

Estudo de coorte | Gravidade da COVID-19 e trajetória da morbidade da saúde mental em populações de pacientes de 6 nações.

27 Abr, 2022 | 16:35h

Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study – The Lancet Public Health

Comunicado de imprensa: Study suggests association between severe COVID-19 and long-term mental health outcomes 16 months after an illness – Lancet

Comentário: Lasting depression and anxiety can follow severe case of Covid – NBC News

 

Comentário no Twitter (fio – clique para saber mais)

In our study published in the @TheLancetPH, we found that a mild course of acute illness (never bedridden due to #COVID19) was associated with a persistently lower risk of adverse #mentalhealth outcomes. https://t.co/aHBQTaOi4K

Several factors might contribute to this pattern🔽

— COVIDMENT research project (@COVIDMENT) April 11, 2022

 

---

Sim, recaídas após Paxlovid acontecem – e agora?

27 Abr, 2022 | 16:33h

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

 

Comentário no Twitter

Some additional thoughts about relapsing Covid19 after treatment with Paxlovid.

Bottom line — *lots* of unknowns, starting w/ how often it happens.

Looking forward to @pfizer sharing further data on the relapsing cases from their EPIC-HR study. https://t.co/1MMhqn4elw

— Paul Sax (@PaulSaxMD) April 25, 2022

 

---

Estudo de coorte | Efetividade de doses de reforço homólogas vs. heterólogas para vacina com SARS-CoV-2 inativado.

27 Abr, 2022 | 16:26h

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study – The Lancet Global Health

Comentários:

COVID-19 vaccine booster strategy: striving for best practice – The Lancet Global Health

Covid-19: Mix and match booster vaccination approach offers best protection, study reports – The BMJ

 

Comentário no Twitter

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study https://t.co/0k7WlphoDV Heterologous booster provided ⬆️ protection than homologous one, especially when Coronavac vaccine had been used.

— Carlos del Rio (@CarlosdelRio7) April 25, 2022

 

---

Por que a variante Ômicron geralmente não acomete a função olfatória? Implicações para a patogênese da anosmia na COVID-19.

27 Abr, 2022 | 16:25h

Why does the Omicron Variant Largely Spare Olfactory Function? Implications for the Pathogenesis of Anosmia in COVID-19 – The Journal of Infectious Diseases

---

Estudo de coorte | Vacinação contra COVID-19 durante o início da gestação não foi associada com risco aumentado de anomalias fetais congênitas.

27 Abr, 2022 | 15:42h

Association of COVID-19 Vaccination During Early Pregnancy With Risk of Congenital Fetal Anomalies – JAMA Pediatrics

Comentários:

COVID vaccine in early pregnancy not tied to birth defects – CIDRAP

No Sign That COVID Vaccine in Pregnancy Raises Birth Defect Risk – HealthDay

---

Reinfecções por SARS-CoV-2: visão geral da eficácia e duração da imunidade natural e híbrida.

27 Abr, 2022 | 15:40h

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity – Environmental Research

Estudos relacionados: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open E Comentários: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services E COVID-19 infection may offer similar immunity as vaccination – CIDRAP

---

Revisão sistemática | Desempenho de sensores portáteis na detecção de infecção por SARS-CoV-2.

27 Abr, 2022 | 15:38h

The performance of wearable sensors in the detection of SARS-CoV-2 infection: a systematic review – The Lancet Digital Health

 

Comentário no Twitter

A missed opportunity for Covid early detection and tracking, inexpensively, passively, at scalehttps://t.co/4cDxlps7AM systematic review of wearable sensors (smartwatch or fitness bands worn or owned by > 80 million Americans) @LancetDigitalH pic.twitter.com/sy1rArB5fE

— Eric Topol (@EricTopol) April 22, 2022

Sob licença de (CC BY 4.0)

---

OMS recomenda o nirmatrelvir-ritonavir para o tratamento da COVID-19 e pede para uma maior distribuição geográfica.

25 Abr, 2022 | 12:47h

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

Ver também:

A living WHO guideline on drugs for covid-19 – The BMJ

Therapeutics and COVID-19: living guideline – World Health Organization

Conteúdos relacionados:

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

 

Comentário no Twitter

🔥 Our latest @WHO living guidance on drugs for #COVID19, with new recommendations for nirmatrelvir-ritonavir & updated recommendation for remdesivir in non-severe illness.@bmj_latest: https://t.co/KuJjwzeTPV@WHO: https://t.co/n3iQx3pdmY@theMAGICapp: https://t.co/dA7YYzeAZ1 pic.twitter.com/LvAhJf70UY

— Arnav Agarwal (@ArnavAgarwalMD) April 21, 2022

 

---

Análise longitudinal de dados de 15 países | Rigor das políticas e saúde mental durante a pandemia de COVID-19.

25 Abr, 2022 | 12:39h

Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries – The Lancet Public Health

Comunicado de imprensa: Stricter COVID-19 measures associated with negative mental health effects and lower opinion of government’s pandemic response, new research suggests – The Lancet

Comentário: Stricter Pandemic Policies Took Toll on Mental Health — Women tended to be more affected than men – MedPage Today

---

Estudo randomizado | AZD7442 (tixagevimabe–cilgavimabe) intramuscular para prevenir Covid-19.

25 Abr, 2022 | 12:29h

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

AZD7442 (tixagevimab/cilgavimab) found to have about 76% efficacy in preventing symptomatic Covid-19 infection. https://t.co/8tmvz3xI4I pic.twitter.com/fOegZjBRA6

— NEJM (@NEJM) April 20, 2022

 

---